CD4+ T-cell count at antiretroviral therapy initiation in the “treat all” era in rural South Africa: an interrupted time series analysis

Article  (Accepted Version)
CD4+ T-cell count at antiretroviral therapy initiation in the “treat all” era in rural South Africa: an interrupted time series analysis

Running title: CD4 at ART initiation in South Africa

H. Manisha Yapa*1,2, Hae-Young Kim2,3, Kathy Petoumenos1, Frank A. Post4, Awachana Jiamsakul1, Jan-Walter De Neve5, Frank Tanser2,6,7,8, Collins Iwuji2,8, Kathy Baisley2,10, Maryam Shahmanesh2,11, Deenan Pillay2,12, Mark J. Siedner2,6,13, Till Bärnighausen†2,5,11,14, Jacob Bor‡§2,15

1 The Kirby Institute, University of New South Wales Sydney, Australia
2 Africa Health Research Institute, KwaZulu-Natal, South Africa
3 New York University Grossman School of Medicine, NY, USA
4 King’s College Hospital NHS Foundation Trust, London, UK
5 Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, University of Heidelberg, Germany
6 School of Nursing and Public Health, University of KwaZulu-Natal, South Africa
7 Lincoln International Institute for Rural Health, University of Lincoln, UK
8 Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, South Africa
9 Department of Global Health and Infection, Brighton and Sussex Medical School, UK
10 Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK
11 Institute for Global Health, University College London, UK
12 Division of Infection & Immunity, University College London, London, UK
13 Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
14 Harvard T.H. Chan School of Public Health, Boston, MA, USA
15 Departments of Global Health and Epidemiology, Boston University, MA, USA

‡ Joint senior authors
* Corresponding author
§ Alternate corresponding author
Level 6, Wallace Wurth Building, University of New South Wales
High Street, Kensington NSW 2052
Australia
Email: myapa@kirby.unsw.edu.au

HYK: hae-young.kim@nyulangone.org
KP: kpetoumenos@kirby.unsw.edu.au
FAP: frank.post@kcl.ac.uk
AJ: ajiamsakul@kirby.unsw.edu.au
JWDN: janwalter.deneve@uni-heidelberg.de
FT: ftanser@lincoln.ac.uk
CI: c.iwuji@bsms.ac.uk
KB: kathy.baisley@lshtm.ac.uk
MS: m.shahmanesh@ucl.ac.uk
DP: d.pillay@ucl.ac.uk
Key points

UTT led to an immediate increase in CD4 count at ART initiation in rural South Africa, with modest long-term effects. Men initiated ART at lower CD4 counts than women. UTT must be combined with other interventions to sustain early ART initiation.
Abstract

Background
South Africa implemented universal test and treat (UTT) in September 2016 in an effort to encourage earlier initiation of antiretroviral therapy (ART).

Methods
We therefore conducted an interrupted time series (ITS) analysis to assess the impact of UTT on mean CD4 count at ART initiation among adults ≥16 years old attending public sector primary care services in rural South Africa between July 2014 and March 2019.

Results
Among 20,599 individuals (69% women), CD4 counts were available for 74%. Mean CD4 at ART initiation increased from 317.1 cells/µL (95% confidence interval, CI, 308.6 to 325.6)—one to eight months prior to UTT—to 421.0 cells/µL (95% CI 413.0 to 429.0) one to twelve months after UTT, including an immediate increase of 124.2 cells/µL (95% CI 102.2 to 146.1). However, mean CD4 count subsequently fell to 389.5 cells/µL (95% CI 381.8 to 397.1) 13 to 30 months after UTT, but remained above pre-UTT levels. Men initiated ART at lower CD4 counts than women (-118.2 cells/µL, 95% CI -125.5 to -111.0) throughout the study.

Conclusions
Although UTT led to an immediate increase in CD4 count at ART initiation in this rural community, the long-term effects were modest. More efforts are needed to increase initiation of ART early in HIV infection, particularly among men.
Introduction

“Universal Test and Treat” (UTT) aims to rapidly reduce AIDS-related deaths and incident HIV infections [1]. CD4+ T-cell counts are no longer required to determine antiretroviral therapy (ART) eligibility among people with HIV [2, 3]. However, there are strong clinical indications to continue baseline CD4 testing—even with rapid ART initiation (ART initiation within seven days of HIV diagnosis) [4]: (i) the CD4 count provides critical information on immune status and risk of opportunistic infections, enabling timely clinical interventions [2, 3] and disease care packages via a public health approach [4], as clinical stage does not accurately reflect actual immune status [5]; (ii) many individuals in low- and middle-income countries (LMIC) still present late to care [6, 7]; (iii) many individuals re-engaging with care after treatment interruption have advanced HIV [8]; and (iv) risk of mortality is highest during the first few months of ART among those with lower CD4 counts at initiation [9, 10].

For people with HIV to initiate ART early in HIV infection, they must first know their HIV status, link to care, and initiate ART. One summary measure of the timing of ART initiation in relation to HIV seroconversion is CD4 count at ART initiation. Unlike previous requirements for regular CD4 measurements until ART eligible, under UTT we expect most individuals to have a single CD4 measurement, their baseline CD4 measurement, which serves the dual function of CD4 count at diagnosis and CD4 at ART initiation. Two previous studies in sub-Saharan Africa showed mixed results on the impact of CD4 eligibility expansions (to <350 cells/µL) on CD4 count at ART initiation [6, 11]. Moreover globally, while median CD4 counts at ART initiation
increased between 2002 and 2015, they remained <350 cells/µL and increases were larger among women than among men in LMIC [12].

In January 2015, South Africa removed CD4 eligibility criteria for pregnant or breastfeeding women (Option B+) and expanded CD4 eligibility criteria to ≤500 cells/µL for non-pregnant or breastfeeding adults [13]. South Africa implemented UTT in September 2016 [14]. A critical question is whether this ambitious policy change resulted in ART initiation earlier in HIV infection as anticipated.

We hypothesised that CD4 count at ART initiation would increase rapidly after UTT implementation as the backlog of people with HIV previously presenting with CD4 counts >500 cells/µL became eligible for ART. Following this short-term increase, we hypothesised that CD4 counts at ART initiation would remain high and continue increasing. We therefore examined short- and medium-term effects of UTT on mean CD4 count at ART initiation among men and women attending public sector primary care clinics in rural South Africa.

Methods

Study setting and design

This longitudinal study was conducted in the Hlabisa sub-district of northern KwaZulu-Natal, at 17 nurse-led primary care clinics which are overseen by the local district hospital. CD4 and HIV viral load monitoring are routinely available. HIV prevalence is 30% [15]. Routine clinical data from the South African national ART programme (TIER.Net) were sourced via the Africa Health Research Institute (AHRI) which has an agreement with the Department of Health (DoH) to access routine clinical data for
research purposes. National ART programme data are captured by DoH clerical staff from patient medical records onto the TIER.Net database.

AHRI has operated a longitudinal population health and demographic surveillance system (HDSS) since 2003 in the area [16]. Since 2017, the AHRI HDSS offers home-based HIV testing, linkage-to-care support, and facilitates ART initiation at DoH clinics [17]. Additional information on the study setting is provided in the Supplementary Material.

During all time periods analysed in the present study, South African ART guidelines recommended baseline CD4 counts. Prior to 2015, CD4 testing was required at diagnosis for all adults and then six-monthly until ART eligible [18]. Baseline CD4 testing was also required during the Option B+ era [13]. Even during UTT (September 2016 onwards)—and the move towards ART initiation on the same day as HIV diagnosis—the CD4 count has remained a recommended baseline investigation [19].

Participants

We included all women and men living with HIV aged ≥16 years who commenced ART between 01 July 2014 and 31 March 2019 at the 17 primary care clinics in Hlabisa sub-district.

Outcomes and exposures

The outcome of interest was CD4 count at ART initiation. We defined this as the closest CD4 count to the ART initiation date within a window of up to six months prior to the ART start date, or up to three months after the ART start date.
The main exposure of interest was calendar time by (a) periods of CD4-based ART eligibility according to South African guidelines (Option B+ guideline in January 2015 and UTT guideline in September 2016), and (b) allowing 12 months for each new guideline to assimilate. We therefore divided calendar time as follows: (1) prior to 01 January 2015 (“pre-Option B+”), (2) 01 January 2015 to 31 December 2015 (the 12 months following the Option B+ policy, entitled “Option B+ implementation” which occurred 9–20 months prior to UTT); (3) 01 January 2016 to 31 August 2016 (“pre-UTT” which was 1–8 months prior to UTT), (4) 01 September 2016 to 31 August 2017 (“UTT implementation” which was 1–12 months following UTT), and (5) 01 September 2017 to 31 March 2019 (“post UTT” which was 13–30 months following UTT).

Data sources

We analysed data from the South African national ART clinical database, TIER.Net, which registers and follows all HIV-positive individuals from ART initiation [20]. TIER.Net includes laboratory results, ART regimen, ART switches, and visit dates. Pregnancy status was not available.

Statistical analysis

We first summarised CD4 categories at ART initiation by sex and time period. We also describe time trends in the proportion of individuals initiating ART without a baseline CD4 count, due to concerns that guidelines recommendations may not be adhered to.

We then graphically represent time trends in mean CD4 at ART initiation by sex using flexible semi-parametric regression methods, namely kernel-weighted smoothed polynomial regression [21].
To measure the impact of UTT on CD4 at ART initiation we performed segmented linear regression (interrupted time series analyses, ITS) with a continuous time variable, binary exposure variables for each policy change, and time-by-policy interaction terms [22]. The time-by-policy interaction term reflects the difference in slope between consecutive time periods (trend change) [22]. As each policy change may have taken time to assimilate, we allowed additional trend changes 12 months after each official policy. We adjusted for missing CD4 counts by inverse probability weighting [23]. Specifically, we regressed availability of a within-window CD4 count on age category and clinic attended for ART initiation; we then used the inverse of the predicted probability of having a CD4 within window, in our main ITS regression model. We selected inverse probability weights over imputation methods to avoid making assumptions about unobserved reasons for missingness.

We also adjusted for sex in our main ITS regression model. Using regression post-estimation commands, we estimated average CD4 counts and actual trends (slopes) for each time period. We performed all statistical analysis in Stata 15.0 (StataCorp. 2017. College Station, TX: StataCorp LLC).

Ethical approvals

Ethical approvals were obtained from the University of KwaZulu-Natal Biomedical Research Ethics Committee (BE290/16) and the University of New South Wales Human Research Ethics Committee (HC17847).

Results

A total of 20,599 individuals (69% women) aged ≥16 years commenced ART between July 2014 and March 2019. This included 10,993 ART initiators after the UTT policy change in September 2016. Median age at ART initiation was 30 (interquartile range,
IQR, 25-38) years. The ART regimen at initiation was tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and efavirenz (EFV) in 98% individuals.

A CD4 count was available for 16,454 (80%) ART initiators, of whom 15,265 had a CD4 count within the specified window (Figure 1). Most (97%) CD4 counts within window were on or prior to the ART start date. Among the 15,265 individuals with a within-window CD4 count, 67% were women (Figure 1).

Men initiating ART were older and had lower CD4 counts than women (Figure 2, Table S1).

A large proportion of individuals initiated ART at CD4 counts ≤200 cells/µL even after UTT. Compared with Option B+ implementation and pre-UTT periods, there were slight reductions in the proportion of individuals initiating ART at CD4 counts ≤200 cells/µL after UTT (Figure 2, Table S1). The total proportion of individuals initiating ART at CD4 counts ≤200 cells/µL ranged from 27–32% prior to the UTT policy change, to 22-26% after the UTT policy change.

The proportion of ART initiators without a baseline CD4 count increased over time. Among the 5334 individuals without a CD4 count within the specified window, 4145 (78%) did not have a CD4 performed at all (Figure 1). The proportion of individuals initiating ART without a CD4 at ART initiation appeared to increase with larger clinic size, and was greater among women (Table S2). There was an increasing time trend in the proportion of all individuals initiating ART without a within-window CD4 count, particularly after September 2016 (Figure 3).
**Time trends in CD4 at ART initiation** are depicted in Figure 4. Women consistently initiated ART at higher CD4 counts than men. There was a marked increase in CD4 at ART initiation immediately after UTT, followed by a downward trend and stabilisation thereafter.

**Impact of policy changes on CD4 count at ART initiation**

**January 2015 to August 2016 (Option B+ implementation and pre-UTT periods)**

Immediately following the policy change in January 2015, mean CD4 at ART initiation increased by 52.7 cells/µL (95% confidence interval [CI] 30.9 to 74.5). There was an upward absolute trend in CD4 at ART initiation during pre-UTT of 3.1 cells/µL per month (95% CI 0.5 to 5.7), Table 1.

**Mean CD4 counts**: The overall mean CD4 was 324.9 cells/µL (95% CI 319.3 to 330.4) during Option B+ implementation (January to December 2015), and 317.1 cells/µL (95% CI 308.6 to 325.6) pre-UTT (January to August 2016). Mean CD4s among women and men are presented in Table S1.

**September 2016 to March 2019 (UTT implementation and post-UTT periods)**

Immediately after the policy switch to UTT in September 2016, there was a marked increase in mean CD4 at ART initiation of 124.2 cells/µL (95% CI 102.2 to 146.1). However, there was a downward absolute trend during the UTT implementation period (September 2016 to August 2017), of 5.6 cells/µL per month (95% CI -7.5 to -3.8). The CD4 trend stabilised post-UTT (Table 1).

**Mean CD4 counts**: The overall mean CD4 count was 421.0 cells/µL (95% CI 413.0 to 429.0) during UTT implementation (September 2016 to August 2017) and 389.5
cells/µL (95% CI 381.8 to 397.1) post-UTT (September 2017 to March 2019). Mean CD4s among women and men are presented in Table S1.

**Men initiated ART at lower CD4 counts than women** after adjusting for policy changes and trend changes (-118.2 cells/µL, 95% CI -125.5 to -111.0), Figure 4.

**Discussion**

We found that mean CD4 count at ART initiation significantly increased immediately after the policy change to UTT. However, the longer-term effect of UTT on mean CD4 count at ART initiation was modest. Following the initial UTT policy rollout, mean CD4 count at ART initiation trended downwards before stabilising approximately 70 cells/µL above pre-UTT baseline CD4 counts. Women consistently initiated ART at higher CD4 counts than men. The proportion of individuals without baseline CD4 counts increased over time, particularly after the policy change to UTT. A large proportion of individuals had advanced HIV at ART initiation despite the eligibility expansion.

The relative proportions of individuals starting ART at lower versus higher CD4 counts influence our observed mean CD4 trends. If the majority of ART initiators had CD4 counts close to or above 500 cells/µL, we would expect the mean CD4 after September 2016 to remain high, and increase over time. Conversely, if lower CD4 count initiators remained the majority, clearing the backlog of previously ineligible individuals would result in a transient increase in mean CD4 before approaching pre-UTT levels, as we observed. However, the more stable mean CD4 after September 2017 about 70
cells/µL above pre-UTT levels attests to an overall medium-term benefit of UTT on earlier ART initiation.

Several health service factors may explain these time trends and sex disparities in CD4 at ART initiation after the UTT policy change. First, there may have been a transient expansion of HIV testing shortly after the UTT policy change at facilities, as illustrated by a process evaluation of a trial conducted at seven clinics in the area [24]. Second, staffing and other resource shortages may have limited timely implementation of the policy, due to limited training or competing clinical priorities [24, 25]. Health workers may have selectively conducted baseline CD4 tests among individuals they perceived to be at risk of advanced HIV, thereby diluting the impact of UTT on CD4 at ART initiation. Third, the historical policy focus on maternal and child health may have contributed to sex disparities in access to care [26, 27]. Inconvenient clinic operating hours or clinics being perceived as less ‘men-friendly’ [28] may have been additional factors. Men are more likely to start ART at later stages of HIV infection than women [29, 30]. Although higher CD4 counts among women may be attributed to earlier HIV diagnosis and treatment during pregnancy, a study in South Africa found that only 7% women initiating ART were pregnant [30].

If people with HIV do not access care at high CD4 counts, they will not initiate ART at high CD4 counts. Although this study did not directly observe time of presentation, other studies have found that many individuals, particularly men, continue to present with low CD4 counts even in the UTT era [31, 32]. Linkage to care within six months of HIV diagnosis is poor in the AHRI catchment area, particularly among men [17]. Prevailing gender norms—including hegemonic masculinity—may partly explain limited HIV care seeking due to perceptions of powerlessness [33].

Among the trials testing implementation of UTT prior to in-country policy change [34-38], median CD4 counts at ART initiation were 320–401 cells/µL, and most participants
were women [34, 39, 40]. Population-level reductions in HIV incidence were demonstrated in two UTT trials that included community-based HIV testing, facilitated linkage to care and patient-centred clinical services [35, 37]. Other studies showed that UTT was associated with ART initiation within 30 days of enrolment in care in some countries but not others [41]. These findings further highlight various health system considerations extraneous to the new policy including health service delivery challenges (including clinic congestion and negative health worker attitudes) [42], individual patient readiness for ART [42], limited uptake of HIV testing due to low perceived risk or fear of stigma [43], or poor linkage to care [34]. Reassuringly, ART eligibility expansions do not appear to crowd out sicker patients despite increased demand for ART services in resource-poor settings [44, 45].

Strengths and limitations

Our study adds to the emerging evidence for the impact of UTT on early ART initiation in sub-Saharan Africa. A key methodological strength of this quasi-experimental ITS analysis is the measurement of outcomes in a large group of individuals attending services in a rural sub-district: assuming population characteristics do not change over time, major sources of confounding are unlikely [22], and enable strong policy conclusions to be drawn. By measuring CD4 count at ART initiation, our outcome also indirectly measures coverage of HIV testing and linkage to care.

Our study has some limitations. First, we sourced CD4 results from the national clinical database, TIER.Net, which relies on manual data entry from paper-based medical records—errors may have been introduced during data entry. It is also unknown whether the large number of missing CD4 counts reflects clinical process failure (from lack of sampling through to poor results turnaround), or gaps in TIER.Net record-keeping [46]. Second, the increasing proportion of missing CD4 values may have
biased our results. However, we addressed this by assigning inverse probability weights in our regression model. Third, our findings may not be generalisable to other settings as factors influencing HIV testing, linkage to care, and ART initiation may differ—for instance, the Hawthorne phenomenon may have occurred at facilities in the sub-district given the regular presence of AHRI research staff in several clinics [47]. Finally, our results may over-estimate the impact of UTT on CD4 counts at initiation due to enhanced outreach activities in the AHRI catchment area.

Policy implications

Efforts to improve early ART initiation through enhanced HIV testing and linkage to care are critical, as are targeted interventions to boost male engagement with services. Interventions such as community-based multi-disease screening [36], patient-centred and personalised services [36], financial incentives [48] and community-based ART initiation and monitoring for men [49], have shown success. Whilst the scalability and sustainability of such interventions are unknown, the need for a holistic approach—such as integrating HIV services with non-communicable disease services (NCDs), addressing the wider determinants of health [50], reducing stigma, strengthening the health system including human and other resources, and improving health service quality—alongside more individualised interventions, remains.

Although CD4 counts no longer influence the decision to start ART, they are crucial to inform opportunistic infection risk stratification, targeted clinical management and advanced disease care packages [3, 4]. This is particularly important given that a third of people with HIV in LMIC still initiate ART late [7, 12] and there is an increased risk of early mortality among those without a pretherapy CD4 count [51].

Conclusions
Although UTT immediately increased earlier ART initiation, the longer-term effect was modest. An increasing proportion of ART initiators did not have a baseline CD4 count, and a large proportion had advanced HIV. Men started ART at lower CD4 counts than women. A multifaceted approach is required to improve service quality and address wider determinants of health. Further research is needed to ascertain the long-term effects of UTT including virologic suppression and HIV incidence.
Notes

Contributors

Study conceptualization: MJS, TB, JB, HMY HYK, FT, CI, MS, and KB. Data curation: HMY. Formal analysis: HMY, JB, TB, KP and AJ. Supervision: FAP, KP, AJ, TB, JB. Writing – original draft: HMY. Writing – review and editing HMY, JB, HYK, KP, FAP, AJ, JWDN, MJS, FT, CI, KB, MS, DP, and TB.

Financial support

This work was supported by core funding to AHRI from the UK Wellcome Trust grant 082384/Z/07/Z and Howard Hughes Medical Institute. The AHRI Population Intervention Platform is partially funded by the South African Population Research Infrastructure Network (SAPRIN), South African Department of Science and Technology.

HMY was supported by an Australian Government Research Training Program (RTP) Scholarship, University of New South Wales, Sydney, Australia. The Kirby Institute is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, UNSW Sydney. JWDN is supported by the Alexander von Humboldt Foundation. TB is supported by the Alexander von Humboldt Professor award, funded by the Federal Ministry of Education and Research; the Wellcome Trust; National Institute of Child Health & Human Development of the National Institutes of Health (R01-HD084233); National Institute on Ageing of the National Institutes of Health (P01-Al112339); and Fogarty International Centre of the National Institutes of Health (D43-TW009775). MJS receives funding and salary support from the NIH (R01-Al124718). JB receives funding and salary support from National Institute of Child Health & Human Development of the National Institutes of Health (R01-HD084233); National Institute of Allergy & Infectious Diseases of the
National Institutes of Health (R01-AI152149); and National Institute of Mental Health of the National Institutes of Health (K01-MH105320).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

The authors wish to thank all study participants and members of the Demographic Health and Surveillance Community, the South African National Department of Health partners and the AHRI Research Data Management team.

Conflicts of interest

FAP reports grants and personal fees from Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme, and Janssen Pharmaceuticals, all outside the submitted work. CI reports grants and non-financial support from Gilead Sciences, outside the submitted work. MS reports grants from the National Institute of Health, Bill & Melinda Gates Foundation, UK Medical Research Council, Wellcome Trust, and Unitaid, all outside the submitted work. All other authors declare they have no potential conflicts of interest. All authors have completed the ICMJE declaration form for Disclosure of Potential Conflicts of Interest.

Availability of data and materials

Access to datasets can be provided by the AHRI research data management team. Requests can be made to the AHRI data repository via the AHRI website at [https://www.ahri.org/research/](https://www.ahri.org/research/).
References

1. WHO. Policy brief: consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection - what’s new. Geneva: World Health Organization; 2015.

2. WHO. Consolidated Guidelines on the Use of Antiretroviral drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2016.

3. Ford N, Meintjes G, Vitoria M, et al. The evolving role of CD4 cell counts in HIV care. Curr Opin HIV AIDS. 2017;12:123-8.

4. WHO. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. Geneva: World Health Organization; 2017.

5. Siika A, McCabe L, Bwakura-Dangarembizi M, et al. Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clin Infect Dis. 2018;66:S140-S6.

6. Siedner MJ, Ng CK, Bassett IV, et al. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. Clin Infect Dis. 2015;60:1120-7.

7. Auld AF, Shiraishi RW, Oboho I, et al. Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment — 10 Countries, 2004–2015. MMWR Morb Mortal Wkly Rep. 2017;66:558-63.

8. Osler M, Hilderbrand K, Goemaere E, et al. The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa. Clin Infect Dis. 2018;66:S118-S25.

9. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-908.

10. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011;6:e28691.

11. Grimsrud A, Cornell M, Schomaker M, et al. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study. J Epidemiol Comm Health. 2016;70:549-55.

12. IeDEA and COHERE Cohort Collaboration. Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis. 2018;66:893-903.

13. National Department of Health South Africa. National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and Adults. Pretoria: National Department of Health; 2015.
14. Implementation of the Universal Test and Treat strategy for HIV positive patients and
differentiated care for stable patients [press release]. Pretoria: National Department of
Health South Africa 2016.

15. Zaidi J, Grapsa E, Tanser F, et al. Dramatic increase in HIV prevalence after scale-up of
antiretroviral treatment. AIDS. 2013;27:2301-5.

16. Tanser F, Hosegood V, Barnighausen T, et al. Cohort Profile: Africa Centre
Demographic Information System (ACDIS) and population-based HIV survey. Int J
Epidemiol. 2008;37:956-62.

17. Baisley KJ, Seeley J, Siedner MJ, et al. Findings from home-based HIV testing and
facilitated linkage after scale-up of test and treat in rural South Africa: young people still
missing. HIV Med. 2019;20:704-8.

18. National Department of Health South Africa. The South African Antiretroviral Treatment
Guidelines: PMTCT guidelines: revised March 2013. Pretoria: National Department of
Health; 2013.

19. Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy guidelines. S
Afr J HIV Med. 2017;18:a776.

20. Osler M, Hilderbrand K, Hennessey C, et al. A three-tier framework for monitoring
antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014;17:18908.

21. Gutierrez RG, Linhart JM, Pitblado JS. From the help desk: Local polynomial regression
and Stata plugins. Stata J. 2003;3:412-9.

22. Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the
evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46:348-55.

23. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing
data. Stat Methods Med Res. 2013;22:278-95.

24. Yapa HM, Dhlomo-Mphatswe W, Moshabela M, et al. A continuous quality improvement
intervention to improve antenatal HIV care testing in rural South Africa: evaluation of
implementation in a real-world setting. Int J Health Policy Manage. 2020;Epub ahead of
print.

25. Michel J, Chimbindi N, Mohlakoana N, et al. How and why policy-practice gaps come
about: a South African universal health coverage context. J Glob Health Reports. 2020;3:e2019069.

26. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our blind spot.
Trop Med Int Health. 2011;16:828-9.

27. Dovel K, Yeatman S, Watkins S, et al. Men’s heightened risk of AIDS-related death: the
legacy of gendered HIV testing and treatment strategies. AIDS. 2015;29:1123-5.
28. Médecines Sans Frontières, South African Medical Unit. HIV care for men: lessons learnt from Médecines Sans Frontières’ experiences in rural and peri-urban South Africa 2019 [Available from: https://samumsf.org/sites/default/files/2019-07/HIV%20Care%20for%20Men.pdf.

29. Druyts E, Dybul M, Kanters S, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS. 2013;27:417-25.

30. Cornell M, Schomaker M, Garone DB, et al. Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Med. 2012;9:e1001304.

31. Bor J, Fox MP, Nattey C, et al. Late presentation persists under UTT in South Africa: a national cohort study. Conference on Retroviruses and Opportunistic Infections; Boston, MA2020. p. Abstract #1134.

32. Carmona S, Bor J, Nattey C, et al. Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort. Clin Infect Dis. 2018;66:S111-S7.

33. Sikweyiya YM, Jewkes R, Dunkle K. Impact of HIV on and the constructions of masculinities among HIV-positive men in South Africa: implications for secondary prevention programs. Glob Health Action. 2014;7:24631.

34. Iwuji CC, Orne-Gliemann J, Larmarange J, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2018;5:e116-e25.

35. Hayes RJ, Donnell D, Floyd S, et al. Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). N Engl J Med. 2019;381:207-18.

36. Havlir DV, Balzer LB, Charlebois ED, et al. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. N Engl J Med. 2019;381:219-29.

37. Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. N Engl J Med. 2019;381:230-42.

38. Khan S, Spiegelman D, Walsh F, et al. Early access to antiretroviral therapy versus standard of care among HIV-positive participants in Eswatini in the public health sector: the MaxART stepped-wedge randomized controlled trial. J Int AIDS Soc. 2020;23:e25610.

39. Bock P, Fatti G, Ford N, et al. Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa. PLoS One. 2018;13:e0195127.
40. Lebelonyane R, Bachanas P, Block L, et al. Rapid antiretroviral therapy initiation in the Botswana Combination Prevention Project: a quasi-experimental before and after study. Lancet HIV. 2020;7:e545-53.

41. Tymejczyk O, Brazier E, Yiannoutsos CT, et al. Changes in rapid HIV treatment initiation after national "treat all" policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis. PLoS Med. 2019;16:e1002822.

42. Seeley J, Bond V, Yang B, et al. Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa. AIDS Behav. 2019;23:929-46.

43. De Allegri M, Agier I, Tiendrebeogo J, et al. Factors Affecting the Uptake of HIV Testing among Men: A Mixed-Methods Study in Rural Burkina Faso. PLoS One. 2015;10:e0130216.

44. Kluberg SA, Fox MP, LaValley M, et al. Do HIV treatment eligibility expansions crowd out the sickest? Evidence from rural South Africa. Trop Med Int Health. 2018;23:968-79.

45. Mody A, Sikazwe I, Czaicki NL, et al. Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia. PLoS Med. 2018;15:e1002574.

46. Etoori D, Wringe A, Kabudula CW, et al. Misreporting of Patient Outcomes in the South African National HIV Treatment Database: Consequences for Programme Planning, Monitoring, and Evaluation. Front Public Health. 2020;8:100.

47. Wickström G, Bendix T. The "Hawthorne effect" - what did the original Hawthorne studies actually show? Scand J Work Environ Health. 2000;26:363-7.

48. Tanser FC, Kim HY, Mathenjwa T, et al. Home-Based Intervention to Test and Start (HITS): a community-randomized controlled trial to increase HIV testing uptake among men in rural South Africa. J Int AIDS Soc. 2021;24:e25665.

49. Barnabas RV, Szpiro AA, van Rooyen H, et al. Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. Lancet Glob Health. 2020;8:e1305-15.

50. Bekker L-G, Alleyne G, Baral S, et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission. Lancet. 2018;392:312-58.

51. Sikombe K, Eshun-Wilson I, Koyuncu A, et al. Early mortality in HIV-infected patients initiating ART without a pretherapy CD4. Conference on Retroviruses and Opportunistic Infections; Seattle, Washington2019. p. Abstract #148.
### Table 1. Interrupted time series regression: mean CD4 at ART initiation by time period

|                         | Pre-Option B+ (Jul 2014 – Dec 2014) | Option B+ implementation (Jan 2015 – Dec 2015) | Pre-UTT (Jan 2016 – Aug 2016) | UTT implementation (Sep 2016 – Aug 2017) | Post-UTT (Sep 2017 – Mar 2019) |
|-------------------------|-------------------------------------|-----------------------------------------------|--------------------------------|------------------------------------------|-------------------------------|
| **Coefficient**         | Coefficient (95% CI)                | Coefficient (95% CI)                          | Coefficient (95% CI)          | Coefficient (95% CI)                    | Coefficient (95% CI)          |
|                         | p-value                             | p-value                                       | p-value                       | p-value                                  | p-value                       |
| Underlying time trend   | -1.5                                | N/A                                           | N/A                           | N/A                                      | N/A                           |
|                         | (-7.8 to 4.9)                       |                                               |                               |                                          |                               |
|                         | *p*=0.647                           |                                               |                               |                                          |                               |
| Level change**          | N/A                                 | 52.7                                          | N/A                           | 124.2                                    | N/A                           |
|                         | *(30.9 to 74.5)*                     |                                               |                               | *(102.2 to 146.1)*                     |                               |
|                         | *p*<0.001                           |                                               |                               | *p*<0.001                               |                               |
| Trend change§           | N/A                                 | -1.7                                          | 6.3                           | -8.7                                     | 6.6                           |
|                         | *(−8.3 to 4.8)*                      |                                               | *(2.6 to 10.0)*               | *(−11.9 to −5.5)*                       | *(3.9 to 9.3)*                |
|                         | *p*=0.603                           |                                               | *p*=0.001                     | *p*<0.001                               | *p*<0.001                     |
| Absolute trend‡         | -1.5                                | -3.2                                          | 3.1                           | -5.6                                     | 1.0                           |
|                         | *(−7.8 to 4.9)*                      |                                               | *(−4.7 to −1.7)*              | *(−7.4 to −3.8)*                        | *(−0.3 to 2.2)*               |
|                         | *p*=0.647                           |                                               | *p*=0.001                     | *p*<0.001                               | *p*<0.122                    |

* The underlying time trend refers to the ‘baseline’ trend of CD4 at ART initiation in the analysis. Based on our models, this refers to the time trend in CD4 at ART initiation during the pre-Option B+ period. Subsequent ‘absolute’ time trends for each study period are calculated from this baseline, drawing on the modelled trend changes as described below.

** Level changes were modelled at immediate policy change (Option B+ policy change and UTT policy change), but not at 12 months after implementation of the policy.

§ Each trend change is the change in trend relative to the (absolute) trend in the time period immediately preceding it. Therefore, the trend change for Option B+ implementation relative to the pre-Option B+ trend is -1.7 cells/µL, and the trend change in pre-UTT relative to Option B+ implementation is +6.3 cells/µL.

‡ Absolute trends were calculated using regression post-estimation commands (\texttt{lincom} in Stata). For example, the absolute trend for Option B+ implementation = pre-Option B+ time trend plus Option B+ implementation trend change; the absolute trend for pre-UTT = pre-Option B+ time trend plus Option B+ implementation trend change plus pre-UTT trend change.

The regression model included inverse probability weights for availability of a CD4 count within window, and a covariate for sex.

ART, antiretroviral therapy; CI, confidence interval; N/A, not applicable; UTT, Universal Test and Treat
Figure 1. Participant flow diagram for inclusion in regression models

ART, antiretroviral therapy
Figure 2. CD4 categories overall and by sex. (a) overall; (b) men; (c) women.
Figure 3. Time trends in proportion of individuals without a CD4 recorded within window.
Dashed vertical lines depict policy change: January 2015, CD4 eligibility cut-off ≤500 cells/µL for adults or Option B+ for pregnant/ breastfeeding women (Option B+ era); September 2016, Universal Test and Treat (UTT).
ART, antiretroviral therapy
Figure 4. CD4 at ART initiation among women and men
Dashed vertical lines depict policy change: January 2015, CD4 eligibility cut-off ≤500 cells/µL for adults or Option B+ for pregnant/breastfeeding women (Option B+ era); September 2016, Universal Test and Treat (UTT) ART, antiretroviral therapy

Figure titles and legends
Figure 1. Participant flow diagram for inclusion in regression models
ART, antiretroviral therapy

Figure 2. CD4 categories overall and by sex. (a) overall; (b) men; (c) women.

Figure 3. Time trends in proportion of individuals without a CD4 recorded within window.
Dashed vertical lines depict policy change: January 2015, CD4 eligibility cut-off ≤500 cells/µL for adults or Option B+ for pregnant/ breastfeeding women (Option B+ era); September 2016, Universal Test and Treat (UTT).
ART, antiretroviral therapy

Figure 4. CD4 at ART initiation among women and men
Dashed vertical lines depict policy change: January 2015, CD4 eligibility cut-off ≤500 cells/µL for adults or Option B+ for pregnant/ breastfeeding women (Option B+ era); September 2016, Universal Test and Treat (UTT)
ART, antiretroviral therapy